EIT Crisis Response Initiative Budget: EUR 500 000
Innovation: The development of a novel therapy to treat rhinitis, a nasal inflammatory disease that affects 40% of the global population. Currently, treatment is limited to over-the-counter (OTC) products and an invasive surgery. The NEUROMARK™ System is instead designed to treat rhinitis through targeted, localised, multipoint application of RF energy in the nasal cavity. Due to COVID-19, without the Start-up Rescue Instrument funding, Neurent would not be able to continue the most time critical activities, maintaining the original timelines for their clinical study to build their evidence base.
Expected Results: To establish the NEUROMARK™ system as the go-to therapy for patients that are eligible for surgical intervention, which can then be expanded to treat other inflammatory chronic conditions in the long-term.